《藥理學(xué)現(xiàn)況》（Cophar）發(fā)表了權(quán)威、全面和系統(tǒng)的評(píng)論。Cophar幫助專(zhuān)家了解藥理學(xué)和藥物發(fā)現(xiàn)的最新進(jìn)展，并提供清晰易讀的綜合信息。專(zhuān)家作者從今天出版的不斷擴(kuò)大的信息量中注釋最有趣的論文，節(jié)省了寶貴的時(shí)間，并使讀者對(duì)重要領(lǐng)域有了深刻的了解。Cophar是當(dāng)前意見(jiàn)和研究（Co+Re）系列期刊的一部分，是新的初級(jí)研究、開(kāi)放獲取期刊、藥理學(xué)和藥物發(fā)現(xiàn)（Crphar）的當(dāng)前研究的伙伴。Cophar將藥理學(xué)的主題分成主題部分，每一部分每年進(jìn)行一次回顧。每個(gè)部分的空間大小與其重要性有關(guān)。主題包括神經(jīng)科學(xué)、心血管和腎臟、呼吸、肌肉骨骼、癌癥、免疫調(diào)節(jié)、抗感染、新技術(shù)、胃腸、內(nèi)分泌和代謝疾病。該雜志以愛(ài)思唯爾在科學(xué)出版方面的卓越聲譽(yù)和長(zhǎng)期致力于傳播以改善人類(lèi)健康為目標(biāo)的可再生生物醫(yī)學(xué)研究為基礎(chǔ)。

Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR).COPHAR divides the subject of pharmacology into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance. Themes include neurosciences; cardiovascular and renal; respiratory; musculoskeletal; cancer; immunomodulation; anti-infectives; new technologies; gastrointestinal; endocrine; and metabolic diseases.The journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.